 | • レポートコード：D0804-14755 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、120ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、抗腫瘍薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。抗腫瘍薬の種類別市場規模（細胞毒性薬、非細胞毒性薬）、用途別市場規模（アルキル化剤、代謝拮抗薬、白金抗腫瘍薬、アントラサイクリン系抗腫瘍薬、微小管安定剤、内分泌療法薬、免疫療法薬、遺伝子治療薬、標的抗腫瘍薬）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Roche、Takeda、Bristol-Myers Squibb、Novartis、Pfizer、Celgene、AstraZeneca、Johnson & Johnson、Amgen、Eli Lilly、Biogen Idec、Otsuka、Astellas、Eisai、Bayer、Merck & Co、Teva、Sanofi ・地域別グローバル市場分析 2015年-2020年 ・抗腫瘍薬の北米市場（アメリカ、カナダ、メキシコ） ・抗腫瘍薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・抗腫瘍薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・抗腫瘍薬の南米市場（ブラジル、アルゼンチン） ・抗腫瘍薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：細胞毒性薬、非細胞毒性薬 ・用途別分析：アルキル化剤、代謝拮抗薬、白金抗腫瘍薬、アントラサイクリン系抗腫瘍薬、微小管安定剤、内分泌療法薬、免疫療法薬、遺伝子治療薬、標的抗腫瘍薬 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Anti-tumor Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Anti-tumor Drug sales will be xx in 2020 from Anti-tumor Drug million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Anti-tumor Drug market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Anti-tumor Drug industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Anti-tumor Drug and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Anti-tumor Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Anti-tumor Drug market has been segmented into:
Cytotoxic Drugs
Non-cytotoxic Drugs
By Application, Anti-tumor Drug has been segmented into:
Alkylating Agents
Anti-metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline antitumor drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Anti-tumor Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Anti-tumor Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Anti-tumor Drug market.
The report offers in-depth assessment of the growth and other aspects of the Anti-tumor Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Anti-tumor Drug Market Share Analysis
Anti-tumor Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Anti-tumor Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Anti-tumor Drug sales, revenue and market share for each player covered in this report.
The major players covered in Anti-tumor Drug are:
Roche
Takeda
Bristol-Myers Squibb
Novartis
Pfizer
Celgene
AstraZeneca
Johnson & Johnson
Amgen
Eli Lilly
Biogen Idec
Otsuka
Astellas
Eisai
Bayer
Merck & Co
Teva
Sanofi
1 Anti-tumor Drug Market Overview
1.1 Product Overview and Scope of Anti-tumor Drug
1.2 Classification of Anti-tumor Drug by Type
1.2.1 Global Anti-tumor Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Anti-tumor Drug Revenue Market Share by Type in 2019
1.2.3 Cytotoxic Drugs
1.2.4 Non-cytotoxic Drugs
1.3 Global Anti-tumor Drug Market by Application
1.3.1 Overview: Global Anti-tumor Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Alkylating Agents
1.3.3 Anti-metabolism Drugs
1.3.4 Platinum Antineoplastic Agents
1.3.5 Anthracycline antitumor drugs
1.3.6 Microtubule Stabilizer
1.3.7 Endocrine Therapy Drugs
1.3.8 Immunotherapy Drugs
1.3.9 Gene Therapy Drugs
1.3.10 Targeted Antineoplastic Drugs
1.4 Global Anti-tumor Drug Market by Regions
1.4.1 Global Anti-tumor Drug Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Anti-tumor Drug (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Anti-tumor Drug Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Anti-tumor Drug Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Anti-tumor Drug Industry Impact
1.5.1 COVID-19 Potential Implications for the Anti-tumor Drug
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Anti-tumor Drug
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Roche SWOT Analysis
2.1.4 Roche Product and Services
2.1.5 Roche Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Takeda SWOT Analysis
2.2.4 Takeda Product and Services
2.2.5 Takeda Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb SWOT Analysis
2.3.4 Bristol-Myers Squibb Product and Services
2.3.5 Bristol-Myers Squibb Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pfizer SWOT Analysis
2.5.4 Pfizer Product and Services
2.5.5 Pfizer Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.6 Celgene
2.6.1 Celgene Details
2.6.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Celgene SWOT Analysis
2.6.4 Celgene Product and Services
2.6.5 Celgene Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 AstraZeneca SWOT Analysis
2.7.4 AstraZeneca Product and Services
2.7.5 AstraZeneca Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.8 Johnson & Johnson
2.8.1 Johnson & Johnson Details
2.8.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Johnson & Johnson SWOT Analysis
2.8.4 Johnson & Johnson Product and Services
2.8.5 Johnson & Johnson Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Amgen SWOT Analysis
2.9.4 Amgen Product and Services
2.9.5 Amgen Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Eli Lilly SWOT Analysis
2.10.4 Eli Lilly Product and Services
2.10.5 Eli Lilly Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.11 Biogen Idec
2.11.1 Biogen Idec Details
2.11.2 Biogen Idec Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Biogen Idec SWOT Analysis
2.11.4 Biogen Idec Product and Services
2.11.5 Biogen Idec Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.12 Otsuka
2.12.1 Otsuka Details
2.12.2 Otsuka Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Otsuka SWOT Analysis
2.12.4 Otsuka Product and Services
2.12.5 Otsuka Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.13 Astellas
2.13.1 Astellas Details
2.13.2 Astellas Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Astellas SWOT Analysis
2.13.4 Astellas Product and Services
2.13.5 Astellas Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.14 Eisai
2.14.1 Eisai Details
2.14.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Eisai SWOT Analysis
2.14.4 Eisai Product and Services
2.14.5 Eisai Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.15 Bayer
2.15.1 Bayer Details
2.15.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Bayer SWOT Analysis
2.15.4 Bayer Product and Services
2.15.5 Bayer Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.16 Merck & Co
2.16.1 Merck & Co Details
2.16.2 Merck & Co Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Merck & Co SWOT Analysis
2.16.4 Merck & Co Product and Services
2.16.5 Merck & Co Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.17 Teva
2.17.1 Teva Details
2.17.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Teva SWOT Analysis
2.17.4 Teva Product and Services
2.17.5 Teva Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
2.18 Sanofi
2.18.1 Sanofi Details
2.18.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Sanofi SWOT Analysis
2.18.4 Sanofi Product and Services
2.18.3 Sanofi Anti-tumor Drug Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Anti-tumor Drug Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Anti-tumor Drug Players Market Share
3.2.2 Top 10 Anti-tumor Drug Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Anti-tumor Drug Revenue and Market Share by Regions
4.2 North America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.3 Europe Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.5 South America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
5 North America Anti-tumor Drug Revenue by Countries
5.1 North America Anti-tumor Drug Revenue by Countries (2015-2020)
5.2 USA Anti-tumor Drug Revenue and Growth Rate (2015-2020)
5.3 Canada Anti-tumor Drug Revenue and Growth Rate (2015-2020)
5.4 Mexico Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6 Europe Anti-tumor Drug Revenue by Countries
6.1 Europe Anti-tumor Drug Revenue by Countries (2015-2020)
6.2 Germany Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.3 UK Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.4 France Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.5 Russia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
6.6 Italy Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Anti-tumor Drug Revenue by Countries
7.1 Asia-Pacific Anti-tumor Drug Revenue by Countries (2015-2020)
7.2 China Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.3 Japan Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.4 Korea Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.5 India Anti-tumor Drug Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
8 South America Anti-tumor Drug Revenue by Countries
8.1 South America Anti-tumor Drug Revenue by Countries (2015-2020)
8.2 Brazil Anti-tumor Drug Revenue and Growth Rate (2015-2020)
8.3 Argentina Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Anti-tumor Drug by Countries
9.1 Middle East & Africa Anti-tumor Drug Revenue by Countries (2015-2020)
9.2 Saudi Arabia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9.3 UAE Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9.4 Egypt Anti-tumor Drug Revenue and Growth Rate (2015-2020)
9.5 South Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Anti-tumor Drug Revenue and Market Share by Type (2015-2020)
10.2 Global Anti-tumor Drug Market Forecast by Type (2019-2024)
10.3 Cytotoxic Drugs Revenue Growth Rate (2015-2025)
10.4 Non-cytotoxic Drugs Revenue Growth Rate (2015-2025)
11 Global Anti-tumor Drug Market Segment by Application
11.1 Global Anti-tumor Drug Revenue Market Share by Application (2015-2020)
11.2 Anti-tumor Drug Market Forecast by Application (2019-2024)
11.3 Alkylating Agents Revenue Growth (2015-2020)
11.4 Anti-metabolism Drugs Revenue Growth (2015-2020)
11.5 Platinum Antineoplastic Agents Revenue Growth (2015-2020)
11.6 Anthracycline antitumor drugs Revenue Growth (2015-2020)
11.7 Microtubule Stabilizer Revenue Growth (2015-2020)
11.8 Endocrine Therapy Drugs Revenue Growth (2015-2020)
11.9 Immunotherapy Drugs Revenue Growth (2015-2020)
11.10 Gene Therapy Drugs Revenue Growth (2015-2020)
11.11 Targeted Antineoplastic Drugs Revenue Growth (2015-2020)
12 Global Anti-tumor Drug Market Size Forecast (2021-2025)
12.1 Global Anti-tumor Drug Market Size Forecast (2021-2025)
12.2 Global Anti-tumor Drug Market Forecast by Regions (2021-2025)
12.3 North America Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.4 Europe Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.6 South America Anti-tumor Drug Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Anti-tumor Drug Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Anti-tumor Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Anti-tumor Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Anti-tumor Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Anti-tumor Drug Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Anti-tumor Drug Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Roche Corporate Information, Location and Competitors
Table 7. Roche Anti-tumor Drug Major Business
Table 8. Roche Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 9. Roche SWOT Analysis
Table 10. Roche Anti-tumor Drug Product and Solutions
Table 11. Roche Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Takeda Corporate Information, Location and Competitors
Table 13. Takeda Anti-tumor Drug Major Business
Table 14. Takeda Anti-tumor Drug Total Revenue (USD Million) (2018-2019)
Table 15. Takeda SWOT Analysis
Table 16. Takeda Anti-tumor Drug Product and Solutions
Table 17. Takeda Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 19. Bristol-Myers Squibb Anti-tumor Drug Major Business
Table 20. Bristol-Myers Squibb Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 21. Bristol-Myers Squibb SWOT Analysis
Table 22. Bristol-Myers Squibb Anti-tumor Drug Product and Solutions
Table 23. Bristol-Myers Squibb Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Novartis Corporate Information, Location and Competitors
Table 25. Novartis Anti-tumor Drug Major Business
Table 26. Novartis Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 27. Novartis SWOT Analysis
Table 28. Novartis Anti-tumor Drug Product and Solutions
Table 29. Novartis Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Pfizer Corporate Information, Location and Competitors
Table 31. Pfizer Anti-tumor Drug Major Business
Table 32. Pfizer Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 33. Pfizer SWOT Analysis
Table 34. Pfizer Anti-tumor Drug Product and Solutions
Table 35. Pfizer Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Celgene Corporate Information, Location and Competitors
Table 37. Celgene Anti-tumor Drug Major Business
Table 38. Celgene Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 39. Celgene SWOT Analysis
Table 40. Celgene Anti-tumor Drug Product and Solutions
Table 41. Celgene Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. AstraZeneca Corporate Information, Location and Competitors
Table 43. AstraZeneca Anti-tumor Drug Major Business
Table 44. AstraZeneca Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 45. AstraZeneca SWOT Analysis
Table 46. AstraZeneca Anti-tumor Drug Product and Solutions
Table 47. AstraZeneca Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Johnson & Johnson Corporate Information, Location and Competitors
Table 49. Johnson & Johnson Anti-tumor Drug Major Business
Table 50. Johnson & Johnson Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 51. Johnson & Johnson SWOT Analysis
Table 52. Johnson & Johnson Anti-tumor Drug Product and Solutions
Table 53. Johnson & Johnson Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Amgen Corporate Information, Location and Competitors
Table 55. Amgen Anti-tumor Drug Major Business
Table 56. Amgen Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 57. Amgen SWOT Analysis
Table 58. Amgen Anti-tumor Drug Product and Solutions
Table 59. Amgen Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Eli Lilly Corporate Information, Location and Competitors
Table 61. Eli Lilly Anti-tumor Drug Major Business
Table 62. Eli Lilly Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 63. Eli Lilly SWOT Analysis
Table 64. Eli Lilly Anti-tumor Drug Product and Solutions
Table 65. Eli Lilly Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Biogen Idec Corporate Information, Location and Competitors
Table 67. Biogen Idec Anti-tumor Drug Major Business
Table 68. Biogen Idec Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 69. Biogen Idec SWOT Analysis
Table 70. Biogen Idec Anti-tumor Drug Product and Solutions
Table 71. Biogen Idec Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Otsuka Corporate Information, Location and Competitors
Table 73. Otsuka Anti-tumor Drug Major Business
Table 74. Otsuka Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 75. Otsuka SWOT Analysis
Table 76. Otsuka Anti-tumor Drug Product and Solutions
Table 77. Otsuka Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. Astellas Corporate Information, Location and Competitors
Table 79. Astellas Anti-tumor Drug Major Business
Table 80. Astellas Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 81. Astellas SWOT Analysis
Table 82. Astellas Anti-tumor Drug Product and Solutions
Table 83. Astellas Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. Eisai Corporate Information, Location and Competitors
Table 85. Eisai Anti-tumor Drug Major Business
Table 86. Eisai Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 87. Eisai SWOT Analysis
Table 88. Eisai Anti-tumor Drug Product and Solutions
Table 89. Eisai Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 90. Bayer Corporate Information, Location and Competitors
Table 91. Bayer Anti-tumor Drug Major Business
Table 92. Bayer Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 93. Bayer SWOT Analysis
Table 94. Bayer Anti-tumor Drug Product and Solutions
Table 95. Bayer Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 96. Merck & Co Corporate Information, Location and Competitors
Table 97. Merck & Co Anti-tumor Drug Major Business
Table 98. Merck & Co Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 99. Merck & Co SWOT Analysis
Table 100. Merck & Co Anti-tumor Drug Product and Solutions
Table 101. Merck & Co Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 102. Teva Corporate Information, Location and Competitors
Table 103. Teva Anti-tumor Drug Major Business
Table 104. Teva Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 105. Teva SWOT Analysis
Table 106. Teva Anti-tumor Drug Product and Solutions
Table 107. Teva Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 108. Sanofi Anti-tumor Drug Type and Application
Table 109. Sanofi Anti-tumor Drug Major Business
Table 110. Sanofi Anti-tumor Drug Total Revenue (USD Million) (2017-2018)
Table 111. Sanofi SWOT Analysis
Table 112. Sanofi Anti-tumor Drug Product and Solutions
Table 113. Sanofi Anti-tumor Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 114. Global Anti-tumor Drug Revenue (Million USD) by Players (2015-2020)
Table 115. Global Anti-tumor Drug Revenue Share by Players (2015-2020)
Table 116. Global Anti-tumor Drug Revenue (Million USD) by Regions (2015-2020)
Table 117. Global Anti-tumor Drug Revenue Market Share by Regions (2015-2020)
Table 118. North America Anti-tumor Drug Revenue by Countries (2015-2020)
Table 119. North America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Table 120. Europe Anti-tumor Drug Revenue (Million USD) by Countries (2015-2020)
Table 121. Asia-Pacific Anti-tumor Drug Revenue (Million USD) by Countries (2015-2020)
Table 122. South America Anti-tumor Drug Revenue by Countries (2015-2020)
Table 123. South America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Table 124. Middle East and Africa Anti-tumor Drug Revenue (Million USD) by Countries (2015-2020)
Table 125. Middle East and Africa Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Table 126. Global Anti-tumor Drug Revenue (Million USD) by Type (2015-2020)
Table 127. Global Anti-tumor Drug Revenue Share by Type (2015-2020)
Table 128. Global Anti-tumor Drug Revenue Forecast by Type (2021-2025)
Table 129. Global Anti-tumor Drug Revenue by Application (2015-2020)
Table 130. Global Anti-tumor Drug Revenue Share by Application (2015-2020)
Table 131. Global Anti-tumor Drug Revenue Forecast by Application (2021-2025)
Table 132. Global Anti-tumor Drug Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Anti-tumor Drug Picture
Figure 2. Global Anti-tumor Drug Revenue Market Share by Type in 2019
Figure 3. Cytotoxic Drugs Picture
Figure 4. Non-cytotoxic Drugs Picture
Figure 5. Anti-tumor Drug Revenue Market Share by Application in 2019
Figure 6. Alkylating Agents Picture
Figure 7. Anti-metabolism Drugs Picture
Figure 8. Platinum Antineoplastic Agents Picture
Figure 9. Anthracycline antitumor drugs Picture
Figure 10. Microtubule Stabilizer Picture
Figure 11. Endocrine Therapy Drugs Picture
Figure 12. Immunotherapy Drugs Picture
Figure 13. Gene Therapy Drugs Picture
Figure 14. Targeted Antineoplastic Drugs Picture
Figure 15. Global Anti-tumor Drug Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Anti-tumor Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Anti-tumor Drug Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Anti-tumor Drug Revenue Market Share in 2019
Figure 24. Global Top 10 Players Anti-tumor Drug Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Anti-tumor Drug Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Anti-tumor Drug Revenue Market Share by Regions (2015-2020)
Figure 28. Global Anti-tumor Drug Revenue Market Share by Regions in 2018
Figure 29. North America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 30. Europe Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 32. South America Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 34. North America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 35. North America Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 36. USA Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 37. Canada Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 39. Europe Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 41. Germany Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 42. UK Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 43. France Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 44. Russia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 45. Italy Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 48. China Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 49. Japan Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 50. Korea Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 51. India Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 53. South America Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 54. South America Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 55. Brazil Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Anti-tumor Drug Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Anti-tumor Drug Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 60. UAE Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Anti-tumor Drug Revenue and Growth Rate (2015-2020)
Figure 63. Global Anti-tumor Drug Revenue Share by Type (2015-2020)
Figure 64. Global Anti-tumor Drug Revenue Share by Type in 2019
Figure 65. Global Anti-tumor Drug Market Share Forecast by Type (2021-2025)
Figure 66. Global Cytotoxic Drugs Revenue Growth Rate (2015-2020)
Figure 67. Global Non-cytotoxic Drugs Revenue Growth Rate (2015-2020)
Figure 68. Global Anti-tumor Drug Revenue Share by Application (2015-2020)
Figure 69. Global Anti-tumor Drug Revenue Share by Application in 2019
Figure 70. Global Anti-tumor Drug Market Share Forecast by Application (2021-2025)
Figure 71. Global Alkylating Agents Revenue Growth Rate (2015-2020)
Figure 72. Global Anti-metabolism Drugs Revenue Growth Rate (2015-2020)
Figure 73. Global Platinum Antineoplastic Agents Revenue Growth Rate (2015-2020)
Figure 74. Global Anthracycline antitumor drugs Revenue Growth Rate (2015-2020)
Figure 75. Global Microtubule Stabilizer Revenue Growth Rate (2015-2020)
Figure 76. Global Endocrine Therapy Drugs Revenue Growth Rate (2015-2020)
Figure 77. Global Immunotherapy Drugs Revenue Growth Rate (2015-2020)
Figure 78. Global Gene Therapy Drugs Revenue Growth Rate (2015-2020)
Figure 79. Global Targeted Antineoplastic Drugs Revenue Growth Rate (2015-2020)
Figure 80. Global Anti-tumor Drug Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Anti-tumor Drug Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Anti-tumor Drug Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 84. Europe Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 86. South America Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Anti-tumor Drug Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
緑内障治療薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Anti-glaucoma Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Anti-glaucoma Drug market …- 腫瘍塞栓術の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Tumor Embolization market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tumor Embolization market …
- 抗血管内皮増殖因子（抗VEGF）薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global marke…
- アンチエイジング薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Anti-Ageing Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.2% in the forecast period of 2020 to 2025 and will expected to reach USD 106360 million by 2025, from USD 80490 million in 2019. The Anti-Ageing Drugs m…
- 抗インフルエンザ薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Anti-influenza Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …